Clinical trials: Essential Hypertension.
Essential Hypertension, Chronic Stable Angina
Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure
The purpose of this study is to Evaluate the Safety of DILATREND SR Cap. in Korean Patients with Essential hypertension, Chronic stable angina and Congestive heart failure for 52 weeks.
- Conditions
- Essential Hypertension, Chronic Stable Angina, Congestive Heart Failure
- Trial name
- DELIGHT (NCT03063697)
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg
The purpose of this study is to collect the long-term (12 months) safety data on aliskiren 300 mg when taken in combination with HCTZ 25 mg.
- Trial name
- NCT00171405
- Testing
- aliskiren
- Where
- 10 sites in United States, Belgium and 8 more
- Volunteers
- 250 people
- Sponsor
- Novartis
Hypertension, Stroke
A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan
The primary objective of the study is to evaluate the proportion of hypertensive patients who achieve regulation of their blood pressure (BP) levels according to the European Society of Cardiology / European School of Haematology…
- Trial name
- NCT01562613
- Where
- 84 sites in Greece
- Volunteers
- 533 people
- Sponsor
- Abbott
Hypertension
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension
This study examines the long term safety and efficacy of the Fixed Dose combination BAY98-7106 (nifedipine plus candesartan primarily at the highest dose in development) in patients with moderate to severe hypertension.
- Trial name
- NCT01788358
- Testing
- Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- Where
- 82 sites in United States, Belgium and 4 more
- Volunteers
- 508 people
- Sponsor
- Bayer
Hypertension
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months
- Trial name
- NCT00927537
- Testing
- Telmisartan (Kinzal/Pritor, BAY68-9291), Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide
- Where
- Switzerland
- Volunteers
- 2,052 people
- Sponsor
- Bayer
Essential Hypertension
A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers
This is a randomized, open, single-dose, crossover-design, phase 1, singlecenter study to evaluate bioequivalence after administration of L04RD1 or administration of L04TD3 in healthy volunteers.
- Trial name
- NCT05993806
- Testing
- L04RD1, L04TD3
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Celltrion
Hypertension
Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension
This is an open-label, non-comparative, multi-centre clinical study to evaluate the Efficacy and safety of Metoprolol Succinate prolonged-release tablet (Betaloc Zok) in patients with mild to moderate essential hypertension.
- Trial name
- NCT00861016
- Testing
- metoprolol succinate prolonged-release tablet and felodipine
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Bradycardia, Hypertension, Systolic
Preload and Autonomic Responses With Cardiac Neuromodulation Therapy (CNT) (CS-06)
This investigation will evaluate the effect of RV pacing lead position on cardiac function and the modulation of the autonomic nervous system with Cardiac Neuromodulation Therapy (CNT) pacing signals.
- Trial name
- CS-06 (NCT04463121)
- Testing
- Moderato IPG's CNT pacing signals, CD Leycom Pressure/Volume Combination Catheters
- Where
- Czechia
- Volunteers
- 22 people
- Sponsor
- BackBeat Medical Inc
Essential Hypertension
Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects
1QG2 is a Phase 1 study aiming to assess the safety and tolerability of ascending single/multiple oral doses (SAD \& MAD) in healthy young subjects, the preliminary food interaction and the effect of QGC001 on blood pressure and…
- Trial name
- NCT01900184
- Testing
- QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
- Where
- France
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Quantum Genomics SA
Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure
Positive Care Effect of the Digital Health Assistant ADELE Blood Pressure for Hypertension Patients
High blood pressure (hypertension) can cause damage to vital organs such as the heart, kidneys, eyes, brain and blood vessels. The risk of developing high blood pressure increases with age.
- Conditions
- Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure, Hypertensive Heart Disease Without (Congestive) Heart Failure, Other Secondary Hypertension
- Trial name
- A0007 (NCT06663280)
- Testing
- Digital health assistant ADELE
- Where
- 2 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Alma Phil Gmbh
Hypertension
Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
The purpose of this study is to evaluate the antihypertensive efficacy and changes of neurohormonal markers of fimasartan and atenolol with exaggerated blood pressure response during exercise in essential hypertensive patients.
- Trial name
- NCT01736488
- Testing
- Fimasartan, Atenolol
- Where
- 4 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension
Phase 3 study to examine the relation between antihypertensive effect and baseline factors exploratively, compared to olmesartan medoxomil in patients with essential hypertension.
- Trial name
- NCT02848170
- Testing
- CS-3150, olmesartan medoxomil
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Essential Hypertension
A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers
To evaluate the pharmacokinetic drug interaction after oral concurrent administration of fimasartan and amlodipine in healthy male volunteers
- Trial name
- NCT00938197
- Testing
- Fimasartan, Amlodipine
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide
A 2-Week, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan in Combination with Hydrochlorothiazide in Patients…
- Trial name
- NCT02222480
- Testing
- Fimasartan, Hydrochlorothiazide
- Where
- South Korea
- Volunteers
- 103 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.
- Trial name
- NCT05359068
- Testing
- SPH3127 tablet, Valsartan
- Where
- 40 sites in China
- Volunteers
- 957 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Primary Hypertension
Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension
The purpose of this study is to assess the safety and efficacy of renal denervation with sterile irrigated deflectable ablation catheter used in renal artery in primary hypertension in China.
- Trial name
- NCT03511313
- Testing
- Renal denervation, Renal angiography
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Synaptic Medical Corporation
Hypertension
A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients
Evaluate the diastolic blood pressure lowering effect of combination of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to aliskiren 300 mg.
- Trial name
- NCT00386139
- Testing
- Aliskiren/HCTZ
- Where
- 2 sites in United States, Germany
- Volunteers
- 881 people
- Sponsor
- Novartis
Essential Arterial Hypertension
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on…
- Trial name
- ATHESA (NCT06608472)
- Testing
- N0877, Benicar HCT ® Tablets 40 mg/25 mg
- Sponsor
- Eurofarma Laboratorios S.A.
Hypertension
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.
- Trial name
- NCT00696384
- Testing
- Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
- Where
- 45 sites in United States, Argentina and 1 more
- Volunteers
- 418 people
- Sponsor
- Takeda
Hypertension
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
The objective of this trial is to assess the safety and efficacy of 52 weeks of open-label treatment with the fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg and telmisartan 40 mg plus HCTZ 12.5 mg in patients with…
- Trial name
- NCT00326768
- Testing
- Telmisartan 40 mg/HCTZ 12.5 mg, Telmisartan 40 mg, Telmisartan 80 mg/HCTZ 12.5 mg
- Where
- 3 sites in Japan
- Volunteers
- 184 people
- Sponsor
- Boehringer Ingelheim